Author

Anton Mikhailovich Safonov

Memorial Sloan Kettering Cancer CenterORCID 0000-0002-4100-8071Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1 Genetic & Genomic Medicine· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 4 Research Focus:differential expression· 3 Organism:human· 3 Assay:whole-exome sequencing· 3 Research Focus:variant calling· 2 Research Focus:variant effect prediction· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Antonio MarraiD· 2 shared Bradley Stephen WubbenhorstiD· 2 shared Fresia G. ParejaiD· 2 shared Jorge Sergio Reis-FilhoiD· 2 shared Katherine L. NathansoniD· 2 shared Marc LadanyiiD· 2 shared Pedram RazaviiD· 2 shared Sarat ChandarlapatyiD· 2 shared

Activity by Year

2016-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Antonio MarraORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

APOBEC3 mutagenesis drives therapy resistance in breast cancer

Avantika Gupta, Andrea M. Gazzo, Pier Selenica, Anton Mikhailovich Safonov, Fresia G. Pareja, Edaise M. da Silva, David N. Brown, Hong Shao, Yingjie Zhu, Juber Patel, Juan Blanco-Heredia, Bojana Stefanovska, Michael A. Carpenter, Yanjun Chen, Isabella Vegas, , Sarat Chandarlapaty

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

Nature Genetics · May 16, 2025Peer-reviewedCancer Biology

A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations

Anton Mikhailovich Safonov, Tomoki T. Nomakuchi, Elizabeth Chao, Carolyn Horton, Jill S. Dolinsky, Amal Yussuf, Marcy E. Richardson, Virginia Speare, Shuwei Li, Zoe C. Bogus, Maria Bonanni, Anna C. Raper, Trust Odia, Bradley Stephen Wubbenhorst, Elsa Faulders, , Theodore G. Drivas

The paper identifies a higher prevalence of NF1 pathogenic variants using a genotype-first approach, finding many cases with somatic mosaicism and increased cancer risk.

Nature Communications · Apr 1, 2025Peer-reviewedGenetic & Genomic Medicine

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer

Anton Mikhailovich Safonov, Antonio Marra, Chaitanya Bandlamudi, Ben O’Leary, Bradley Stephen Wubbenhorst, Emanuela Ferraro, Enrico Moiso, Minna Lee, Julia Ah-Reum An, Mark T.A. Donoghue, Marie Will, Fresia G. Pareja, Emily A. Nizialek, Natalia Lukashchuk, Eleni Sofianopoulou, , Pedram Razavi

The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.

bioRxiv · Feb 5, 2024 · PreprintGenomics

Methods for detecting co-mutated pathways in cancer samples to inform treatment selection

Tingting Jiang, Uri Shaham, Fabio Parisi, Ruth Halaban, Anton Mikhailovich Safonov, Harriet M. Kluger, Sherman M. Weissman, Joseph T. Chang, Yuval Kluger

The paper develops a method to detect co-mutated pathways in cancer samples and identifies enriched pathway pairs across six cancer types, suggesting potential mechanisms for immune evasion.

bioRxiv · Oct 22, 2016 · PreprintBioinformatics